TCGA-XF-AAMJ-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 54.86202365
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.640
- HEDGEHOG_SIGNALING+0.470
- MYOGENESIS+0.460
- COAGULATION+0.410
- UV_RESPONSE_DN+0.380
- APICAL_JUNCTION+0.330
- INFLAMMATORY_RESPONSE+0.320
- APICAL_SURFACE+0.280
- PANCREAS_BETA_CELLS+0.280
Top 10 suppressed
- E2F_TARGETS-0.620
- MYC_TARGETS_V1-0.610
- G2M_CHECKPOINT-0.530
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.440
- DNA_REPAIR-0.400
- PI3K_AKT_MTOR_SIGNALING-0.390
- MTORC1_SIGNALING-0.320
- PROTEIN_SECRETION-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.946 |
| 2 | BSR_12_0273_A5_S86 | — | A | 0.918 |
| 3 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.918 |
| 4 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.916 |
| 5 | aMVAC.P_004_TURBT_S222 | — | — | 0.914 |
| 6 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.912 |
| 7 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.910 |
| 8 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.907 |
| 9 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.903 |
| 10 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.640 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| MYOGENESIS | 0.460 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |